Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Once the hottest property in biotech, gene therapy company bluebird bio has been sold for less than $500 million after a long series of setbacks.

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...

Gene therapy developer bluebird bio (NASDAQ:BLUE) announced Friday its plans to become a privately held biotech as part of an M&A agreement with private equity firms, Carlyle Group (NASDAQ:CG) and SK ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

Ancient DNA is telling us more and more about humans and environments long past. Could it also help rescue the future?

The Pro Football Hall of Fame voting bylaws to make it harder for candidates to get inducted, which is bad news for Fred ...

Indiana University will soon need a men’s basketball coach & Texas Tech’s Grant McCasland “fits” IU’s needs, but one.

This important manuscript proposes a new strategy for the identification of new mechanisms of drug resistance based on SAturated Transposon Analysis in Yeast (SATAY), a powerful transposon sequencing ...